Aeterna, Ergomed to co-develop endometrial cancer drug

Ergomed has been selected as the contract clinical development organization to conduct the Phase 3 trial with AEZS-108 in endometrial cancer.

As per the agreement, Ergomed will assume 30% of the clinical and regulatory costs for the Phase 3 trial with AEZS-108 in endometrial cancer.

Ergomed will receive its return on investment based on an agreed single digit percentage of any net income received by Aeterna Zentaris for AEZS-108 in this indication, up to a specified maximum amount.

Aeterna Zentaris president and CEO Juergen Engel said that the company is looking forward to work with Ergomed, which has a proven track record of delivering cost effective and efficient drug development services worldwide.

"This agreement is part of our non-dilutive strategy aimed at minimizing R&D costs while maximizing drug development efficiency," Engel added.

"Our goal for AEZS-108 with this collaboration is to provide a much needed new treatment option to women with late-stage endometrial cancer."